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NetherlandsA B S T R A C TObjectives: To develop a model to predict EuroQol ﬁve-dimensional
questionnaire (EQ-5D) values from clinical chronic obstructive pulmo-
nary disease (COPD) questionnaire (CCQ) scores. Methods: We used
data from three clinical trials (the Randomized Clinical Trial on
Effectiveness of Integrated COPD Management in Primary Care
[RECODE], the Assessment Of Going Home Under Early Assisted
Discharge [GO-AHEAD], and the Health Status Guided COPD Care
[MARCH]). Data were randomly split into an estimation sample and a
validation sample. The conceptual similarity between patient-reported
CCQ and preference-based EQ-5D scores was assessed using correla-
tion and principal-component analysis. Different types of models were
estimated with increasing complexity. We selected the ﬁnal models on
the basis of mean absolute error and root mean square error when
comparing predicted and observed values from the same population
(internal validity) and from different trial populations (external val-
idity). We also developed models for different country-speciﬁc EQ-5D
value sets. Results: The principal-component analysis showed thatee front matter Copyright & 2015, International S
r Inc.
.1016/j.jval.2014.11.006
bmg.eur.nl.
ondence to: Melinde R.S. Boland, Institute for M
us University Rotterdam, P.O. Box 1738, 3000 DR,the CCQ domains functional state and mental state are associated
with four dimensions of the EQ-5D. The EQ-5D dimension pain/
discomfort formed a separate construct on which no CCQ item loaded.
The mean observed EQ-5D values were not signiﬁcantly different from
the mean predicted EQ-5D values in internal validation samples but
did signiﬁcantly differ in external validation samples. The models
underestimated EQ-5D values in milder health states and overesti-
mated them in more severe health states. The predictive ability of the
models was similar across different EQ-5D value sets. Conclusions:
The models can predict mean EQ-5D values that are similar to
observed mean values in a similar population. The overestimating/
underestimating of the low/high EQ-5D values, however, limits its use
in Markov models. Therefore, mapping should be used cautiously.
Keywords: CCQ, EQ-5D, mapping, utility.
Copyright & 2015, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Studies assessing the effectiveness of new chronic obstructive
pulmonary disease (COPD) treatments commonly use disease-
speciﬁc health-related quality-of-life (HRQOL) instruments such
as the St. George’s Respiratory Questionnaire (SGRQ) [1] and the
clinical COPD questionnaire (CCQ) [2]. Preference-based HRQOL,
however, measures such as the EuroQol ﬁve-dimensional ques-
tionnaire (EQ-5D) [3] are often not included in these studies.
Nevertheless, data from such studies frequently form the basis of
post hoc cost-utility analyses that aim to estimate the incremen-
tal costs per quality-adjusted life-year gained. To enable the
calculation of quality-adjusted life-years in the absence of
directly collected EQ-5D data, the SGRQ or CCQ scores from thesestudies need to be converted to utilities. This can be done with a
model or algorithm that maps disease-speciﬁc HRQOL data to EQ-
5D data. This solution has also been recommended by the National
Institute for Health and Care Excellence [4] and is seen as a better
approach than judgments of experts [5]. Before July 2013, 90 studies
estimated 121 mapping models and reported algorithms to allow
other researchers to use them to predict EQ-5D values [6].
A model to map SGRQ scores onto EQ-5D values has been
published [7]. A model to predict EQ-5D values from CCQ data,
however, has not been developed. It is relevant to do so because
the CCQ is increasingly used, not only because it is brief and takes
little time to complete [8] but also because the 2013 revision of
the Global Initiative for Chronic Obstructive Lung Disease guide-
lines recommends the CCQ as one of the options to deﬁneociety for Pharmacoeconomics and Outcomes Research (ISPOR).
edical Technology Assessment, Institute of Health Policy and
Rotterdam, The Netherlands.
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 2 9 9 – 3 0 7300symptom level, that is, one of the three components of the COPD
classiﬁcation [9]. This study aimed to develop a model to predict
EQ-5D values from CCQ scores obtained in clinical trials.Methods
Instruments
CCQ
The CCQ is an instrument to measure HRQOL in patients with
COPD on three domains (symptoms, functional state, and mental
state). The symptoms and functional state domains contain four
items each, and the mental state domain contains two items.
Patients have to respond to each item on a seven-point scale,
resulting in more than 282 million possible health states. Response
options on CCQ items 1 to 6 are as follows: never/hardly ever/a few
times/several times/many times/a great many times/almost all the
time. Response options on CCQ items 7 to 10 are as follows: not
limited at all/very slightly limited/slightly limited/moderately lim-
ited/very limited/extremely limited/totally limited or unable to do.
The total CCQ score and the scores of the domains are calculated
by adding up the item scores and dividing this sum by the number
of items, where 0 is the best and 6 is the worst score [2].
EQ-5D
The EQ-5D is a generic HRQOL questionnaire. It consists of ﬁve
dimensions to describe the current health states of patients:
mobility, self-care, usual activity, pain/discomfort, and anxiety/
depression. Each dimension is measured with one item, and
respondents have to respond to each item on a three-point scale
(no, some, or extreme problems). This results in 243 potential
health states. EQ-5D values are calculated by combining the
responses on each dimension with off-the-shelf preference-based
weights (i.e., a value set). In the base case, we used the Dutch EQ-5D
value set to calculate the EQ-5D values of the patients with COPD.
These EQ-5D values can range from 0.329 to 1, where 0 indicates a
health state equivalent to dead and 1 indicates full health [3,10]. In
the sensitivity analyses, we used UK and US EQ-5D value sets.
Setting and Participants
To include a broad range of patients with different severity levels
of COPD, we combined the data from three trials: the Randomized
Clinical Trial on Effectiveness of Integrated COPD Management in
Primary Care (RECODE), a 2-year, cluster-randomized controlled
trial with 1086 patients recruited from general practice [11]; the
Assessment Of Going Home Under Early Assisted Discharge (GO-
AHEAD) trial, a 3-month, multicenter, randomized trial with 166
patients hospitalized for a COPD exacerbation [12]; and the Health
Status Guided COPD Care (MARCH) trial, a 6-month, randomized
controlled trial with 53 patients recruited from general practice
[13]. Patients completed both the CCQ and the EQ-5D at two
(MARCH), three (GO-AHEAD), and six (RECODE) time points.
Conceptual Similarity
Mapping would be able to appropriately predict EQ-5D values
from the CCQ only if there are no major conceptual differences
between the CCQ and the EQ-5D [14]. Therefore, we ﬁrst inves-
tigated the conceptual (dis)similarities between the EQ-5D dimen-
sions and the CCQ items using Spearman rank correlations and
principal-component analysis (PCA). PCA explores which ques-
tions included in the two instruments are related to each other
and generate information on the same underlying construct. The
CCQ may include items related to domains that are not included
in the EQ-5D and hence will not be reﬂected in changes in thepatient’s EQ-5D value, and vice versa. In the explorative PCA, all
constructs with an eigenvalue of more than 1 were selected [15],
whereas in the conﬁrmatory PCA the number of constructs was
set to ﬁve to investigate whether these ﬁve constructs would
mirror the ﬁve dimensions of the EQ-5D. Eigenvalues of a
construct represent the relative share of variance accounted for
by the construct. The individual items have meaningful loadings
on a construct if their absolute value exceeds 0.40. After extracting
the initial constructs, varimax rotation was used to improve the
differentiation and the interpretability of the results [16].
Model Development
The data set was randomly split into a sample that was used to
estimate the model (50%) and a sample that was used to validate
the estimated model (50%). Thereafter, different types of models
were estimated with increasing complexity. We started with simple
models that predicted the EQ-5D value from the total CCQ score and
the CCQ domain scores. We also investigated models that included
individual items of the CCQ, either as categorical variables or as
dummy variables for the seven possible response options of each
CCQ item. We further tested whether the model improved when
including polynomial terms and patient characteristics (age, Charl-
son comorbidity index [17], and sex) and when the seven-point
response scale of the CCQ was collapsed into a three-point scale by
combining the response options 1 and 2, 3 and 4, and 5, 6, and 7.
These models were estimated using ordinary least squares
(OLS) with backward selection procedures. Variables with a P value
of more than 0.10 were removed. To correct for multiple testing,
Bonferroni corrections were applied to the models with dummy
variables for the seven possible response options of each CCQ item.
Because OLS regression ignores censoring in the EQ-5D values,
we investigated whether Tobit and generalized linear models
performed better than OLS models [18]. The distribution and link
function of these models were selected after comparing the
goodness of ﬁt of models with different speciﬁcations of the
distribution and link functions (i.e., normal, inverse Gaussian,
gamma, Poisson distributions in combination with log and
identity link). Models that had the lowest Akaike’s information
criterion and Bayesian information criterion were selected [19].
To analyze the effect of using repeated measurements of the
same patients as independent observations, we estimated a model
on the basis of 1) the baseline data of the RECODE trial and 2) data
from all measurements in the RECODE trial. In addition, we
estimated models on the basis of 3) data from the GO-AHEAD trial
only (because the patients in that trial are more severely ill) and 4)
data from the combined RECODE, GO-AHEAD, and MARCH trials.
Model Validation
We validated the models that were developed for each data set
(i.e., data sets 1–4 as mentioned above). First, the models were
used to predict EQ-5D values of patients in the validation sample
(internal validation). In addition, the models that were developed
using data from one trial were used to predict EQ-5D values in the
other trials (external validation). Predicted EQ-5D values were
compared with observed EQ-5D values. The mean absolute error
(MAE) was reported for the overall range of observed EQ-5D
values and for observed EQ-5D values in a speciﬁc range; that
is, EQ-5D o 0.25, 0.25 r EQ-5D o 0.50, 0.50 r EQ-5D o 0.75, 0.75
r EQ-5D r 1. We also calculated the root mean square error
(RMSE), which attaches greater weight to larger errors. A scatter
plot of observed and predicted values in the validation sample
was provided, and we tested whether the mean predicted EQ-5D
value signiﬁcantly differed from the mean observed EQ-5D value.
We selected the ﬁnal models on the basis of the MAE and the
RMSE when comparing the predicted and observed EQ-5D values
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different trial populations (external validity). This was done for
models in which EQ-5D values were based on the Dutch value set
and, in sensitivity analyses, for models in which EQ-5D values
were based on the US value set and the UK value set.
Finally, we assessed the precision of the predicted mean
EQ-5D value by applying a bootstrap procedure: 1) we randomly
sampled patients, with replacement, to create a group of size 10,
25, 50, 100, 250, and 500; 2) we computed the mean predicted EQ-
5D value and the mean predicted error for each of the six group
sizes; 3) we repeated steps 1) and 2) 1000 times to generate a
distribution of the group predicted error for each of the six
group sizes.Results
Descriptive Statistics
The patient characteristics are presented in Table 1. Observa-
tions with missing data on the total EQ-5D and/or CCQ score
were excluded, resulting in a study population containing 5751Table 1 – Patient characteristics at baseline and average
different databases.
Characteristic
Patients, n
Observations, n
Age (y)
Men, %
FEV1, % predicted
FEV1 Z50% predicted
FEV1 o50% predicted
Charlson comorbidity index
EQ-5D
Mobility (no/some/extreme problems), %
Self-care (no/some/extreme problems), %
Usual activities (no/some/extreme problems), %
Pain/discomfort (no/some/extreme problems), %
Depression/anxiety (no/some/extreme problems), %
CCQ*
Symptoms
Functional state
Mental state
CCQ-1 Short of breath at rest
CCQ-2 Short of breath doing physical activities
CCQ-3 Concerned about getting a cold or your breathing getting worse
CCQ-4 Depressed (down) because of your breathing problems
CCQ-5 Cough
CCQ-6 Produce phlegm
CCQ-7 Strenuous physical activities
CCQ-8 Moderate physical activities
CCQ-9 Daily activities at home
CCQ-10 Social activities
Note. Values are means  SD unless indicated otherwise.
CCQ, Clinical COPD Questionnaire; COPD, chronic obstructive pulmonary
measurement to indicate the severity of airﬂow obstruction; GO-AHEAD,
Health Status Guided COPD Care; RECODE, Randomized Clinical Trial on
* Response options on CCQ items 1 to 6 are as follows: never (0)/hardly e
times (5)/almost all the time (6). Response options on CCQ items 7 to 1
limited (2)/moderately limited (3)/very limited (4)/extremely limited (5)observations. The patients were mainly elderly (68 years),
included slightly more men (55%), and had moderate airﬂow
obstruction. The mean CCQ score was 1.66  1.04, and the
mean EQ-5D value was 0.75  0.25, whereas the mean EQ-5D
value for a representative sample of the Dutch population has
been estimated at 0.89 [20]. The distribution of EQ-5D values
was left-skewed: 25% of the observations were at 1 (full health),
25% were between 0.8 and 1, 25% were between 0.7 and 0.8, and
25% were between 0.3 and 0.7. The CCQ scores also showed
skewness toward the severe end of the scale: 1% of the CCQ
scores were at 0 (full health), 50% of the observations were
between 0 and 1.5, 25% were between 1.5 and 2.3, and 25% were
between 2.3 and 6. Decreased HRQOL was mainly due to the
CCQ items 2, 5, 6, and 7 (Table 1 gives a description of these
items), and more than 50% of the patients reported some or
extreme problems in the EQ-5D dimensions mobility and pain/
discomfort. The Charlson comorbidity index, a weighted sum
score of the comorbid conditions of a patient, was lower (i.e.,
better) in patients in the GO-AHEAD trial than in patients in the
MARCH trial [21]. Despite this, the rank order from best to
worst mean HRQOL in the trials was MARCH, RECODE, GO-
AHEAD.EQ-5D and CCQ scores of all the time points in the
Total data RECODE GO-AHEAD MARCH
1303 1084 166 53
5751 5268 382 101
68  11 68  11 68  11 64  11
55.0 54.0 61.0 58.5
65.7 67.8 48.3 75.4
76.2 77.7 41.3 94.3
23.8 22.3 58.8 5.7
2.27  1.29 2.34  1.26 1.75  1.09 2.56  1.83
0.75  0.25 0.75  0.25 0.67  0.25 0.88  0.13
48.7/50.8/0.5 49.7/49.9/0.5 30.69/67.5/
1.8
67.3/32.7/0
79.0/19.1/1.9 80.9/17.5/1.6 48.2/45.0/6.8 96.0/4.0/0
58.3/37.5/4.2 60.7/35.8/3.5 23.6/61.3/
15.2
65.3/34.7/0
47.5/41.4/
11.1
46.3/41.9/
11.8
57.9/37.7/4.5 71.3/27.7/
1.0
77.0/20.6/2.4 78.1/19.6/ 2.3 60.7/34.6/4.7 82.2/17.8/0
1.66  1.04 1.61  1.00 2.51  1.17 1.10  0.78
2.13  1.18 2.12  1.18 2.44  1.16 1.68  1.06
1.69  1.37 1.60  1.30 3.07  1.58 0.92  0.94
0.65  1.04 0.59  0.99 1.52  1.39 0.29  0.60
1.18  1.31 1.16  1.30 1.68  1.37 0.64  0.84
2.76  1.73 2.72  1.71 3.54  1.70 2.15  1.62
0.59  1.11 0.53  1.05 1.52  1.55 0.18  0.46
0.71  1.19 0.66  1.14 1.51  1.56 0.41  0.82
2.47  1.58 2.47  1.59 2.54  1.45 2.14  1.72
2.11  1.76 2.12  1.76 2.00  1.64 1.78  1.78
2.82  1.85 2.75  1.82 4.04  1.89 1.92  1.57
1.87  1.63 1.78  1.57 3.22  1.84 1.02  1.30
1.16  1.48 1.05  1.36 2.92  1.94 0.37  0.86
0.91  1.32 0.83  1.24 2.14  1.72 0.39  0.91
disease; FEV1, forced expiratory volume in 1 s, a pulmonary function
Assessment Of Going Home under Early Assisted Discharge; MARCH,
Effectiveness of Integrated COPD Management in Primary Care.
ver (1)/a few times (2)/several times (3)/many times (4)/a great many
0 are as follows: not limited at all (0)/very slightly limited (1)/slightly
/totally limited or unable to do (6).
Table 2 – Mapping algorithm (i.e., regression coefﬁcients) of the recommended models.
Model A (Dutch value set) Model B (Dutch value set)
Variable Β SE P Variable β SE P
Intercept .24995 .06295 0.0001 Intercept .28244 .06506 o0.0001
Response 0 or 1 on CCQ-1 .13716 .06105 0.0259 Response 0 or 1 on CCQ-1 .16570 .06267 0.0089
Response 2 or 3 on CCQ-1 .13146 .05734 0.0230 Response 2 or 3 on CCQ-1 .14444 .05742 0.0128
Response 0 or 1 on CCQ-4 .14506 .05049 0.0046 Response 0 or 1 on CCQ-4 .13021 .05083 0.0113
Response 2 or 3 on CCQ-4 .09468 .05243 0.0726 Response 2 or 3 on CCQ-4 .08218 .05255 0.1196
Response 0 or 1 on CCQ-8 .14845 .05814 0.0115 Response 0 or 1 on CCQ-8 .12698 .05897 0.0327
Response 2 or 3 on CCQ-8 .06910 .03915 0.0793 Response 2 or 3 on CCQ-8 .05938 .03927 0.1323
Response 0 or 1 on CCQ-9 .18815 .04875 0.0002 Response 0 or 1 on CCQ-9 .18981 .04844 0.0001
Response 2 or 3 on CCQ-9 .14164 .03762 0.0002 Response 2 or 3 on CCQ-9 .14809 .03755 0.0001
Male .06658 .03028 0.0292 Male .08202 .03127 0.0095
Charlson comorbidity index .02427 .01340 0.0717
Model C (US value set) Model D (UK value set)
Variable β SE P Variable β SE P
Intercept .94682 .03204 o0.0001 Intercept .95497 .04719 o0.0001
CCQ symptoms2 .00683 .00213 0.0016 CCQ symptoms2 .01041 .00314 0.0011
CCQ functional .06249 .00970 o0.0001 CCQ functional .09133 .01428 o0.0001
CCQ mental2 .01529 .00684 0.0265 CCQ mental2 .02242 .01007 0.0272
CCQ mental3 .00293 .00150 0.0526 CCQ mental3 .00449 .00221 0.0437
Male .05102 .02276 0.0262 Male .07866 .03352 0.0200
Note. CCQ symptoms2 ¼ CCQ symptoms  CCQ symptoms; CCQ mental2 ¼ CCQ mental  CCQ mental; CCQ mental3 ¼ CCQ mental  CCQ
mental  CCQ mental.
CCQ, Clinical COPD Questionnaire; COPD, chronic obstructive pulmonary disease.
Table 3 – Internal validity of the recommended models based on the GO-AHEAD database using different EQ-5D
value sets.
EQ-5D value
set
Dutch model A Dutch model B US model C UK model D
Observed Predicted Observed Predicted Observed Predicted Observed Predicted
Mean EQ-5D .6625 .6843 .6625 .6901 .6993 .7134 .6002 .6161
MAE .1520 .1471 .1211 .1766
RMSE .1983 .1963 .1552 .2289
Mean if observed
EQ-5D o 0.25
.1562 .5181 .1562 .5238 .2190 .5184 .0912 .4224
Mean if 0.25 r
observed EQ-
5D o 0.5
.3513 .5618 .3513 .5567 .3849 .5964 .3101 .5135
Mean if 0.50 r
observed EQ-
5D o 0.75
.6624 .6530 .6624 .6623 .6364 .6439 .6530 .5939
Mean if 0.75 r
observed EQ-
5D r 1
.8566 .7753 .8566 .7821 .8425 .7914 .8841 .7875
MAE if observed
EQ-5D o 0.25
.3618 .3676 .2994 .3311
MAE if 0.25 r
observed EQ-
5D o 0.5
.2113 .2068 .2157 .2283
MAE if 0.50 r
observed EQ-
5D o 0.75
.1254 .1215 .0968 .1387
MAE if 0.75 r
observed EQ-
5D r 1
.1105 .1027 .0993 .1429
EQ-5D, EuroQol ﬁve-dimensional questionnaire; GO-AHEAD, Assessment Of Going Home under Early Assisted Discharge; MAE, mean absolute
error; RMSE, root mean square error.
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The correlation matrix between the two instruments is shown in
Appendix 1 in Supplemental Materials found at http://dx.doi.org/
10.1016/j.jval.2014.11.006. The correlation between total CCQ
scores and EQ-5D values was moderate (0.514). The correlations
were negative because a better score is indicated by a higher
value on the EQ-5D and a lower value on the CCQ. Correlations
between EQ-5D dimensions and the CCQ total score was mostly
lower. Weak correlation (o0.3) was found between the total CCQ
score and the EQ-5D dimension pain/discomfort. The highest
correlation (0.583) was found between the total CCQ score and the
EQ-5D dimension usual activity. The lowest correlations (o0.2)
were those between any of the EQ-5D dimensions and CCQ items
5 and 6 related to cough and phlegm production.
The exploratory PCA showed that four constructs had an
eigenvalue of more than 1 and explained 69% of the total
variance (see Appendix 2 in Supplemental Materials found at
http://dx.doi.org/10.1016/j.jval.2014.11.006). CCQ items 1, 2, 7, 8,
9, and 10, which all related to being active and the impact of
being active on breathlessness, and the EQ-5D dimensions
mobility, self-care, and usual activities all loaded onto the same
construct. CCQ items 3 and 4 related to being concerned and
depressed loaded on the same construct as the EQ-5D dimen-
sion depression/anxiety. CCQ items 5 and 6 related to cough
and phlegm production formed a distinct construct, unrelated
to any of the EQ-5D items. Likewise, the EQ-5D dimensions
pain/discomfort and mobility formed a construct on which
none of the CCQ items loaded. Hence, the EQ-5D dimension
mobility had a loading of more than 0.4 on two constructs. The
two constructs containing both CCQ and EQ-5D items explained
a total variance of 48%.
The conﬁrmatory PCA in which the number of components
was ﬁxed at ﬁve is presented in Appendix 3 in Supplemental
Materials found at http://dx.doi.org/10.1016/j.jval.2014.11.006.
Construct 1 of the exploratory PCA was split into two constructs:
one construct with CCQ items 1, 2, 7, 8, 9, and 10 and one
construct with CCQ items 7, 8, 9, and 10 and EQ-5D dimensions
mobility, self-care, and usual activities.T
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).Models with the Dutch EQ-5D Value Set
The simplest equation for predicting EQ-5D values using the
Dutch value set is the 10-parameter model A in Table 2. This
model, which was based on the GO-AHEAD data set, had the
lowest MAE and RMSE when comparing predicted and observed
EQ-5D values from the same population and from different trial
populations, especially when observed EQ-5D values were below
0.5 (see Appendix 4 in Supplemental Materials found at http://dx.
doi.org/10.1016/j.jval.2014.11.006). Therefore, this model was
chosen as the best model. Model A was able to predict a mean
EQ-5D value that was not signiﬁcantly different from the
observed mean EQ-5D value in the validation data set (Table 3).
In the external validation, the model was able to predict a mean
EQ-5D value that did not signiﬁcantly differ from the mean
observed EQ-5D value in the MARCH data set but the model
was unable to predict an accurate mean EQ-5D value in the
RECODE data set (Table 4). Model A is a classical OLS regression
model because that model outperformed generalized linear
models with different distributions and link functions. Further-
more, using a Tobit model instead of an OLS model increased the
MAE (0.152 vs. 0.161) and the RMSE (0.198 vs. 0.214).
Scatter plots of predicted and observed values for model A are
shown in Figure 1. The scatter plots reveal that the mapping did
not produce accurate predictions of the EQ-5D value on an
individual level, especially not for the more severe health states
(observed EQ-5D values o0.5).
Fig. 1 – Scatter plots of the observed and predicted EQ-5D in Model A based on the GO-AHEAD development data in (I) GO-
AHEAD validation dataset (II) RECODE dataset (III) MARCH dataset. EQ-5D, EuroQol ﬁve-dimensionalquestionnaire; GO-
AHEAD, Assessment Of Going Home under Early Assisted Discharge; GO-AHEAD, Assessment Of Going Home under Early
Assisted Discharge; MARCH; RECODE, Randomized Clinical Trial on Effectiveness of Integrated COPD Management in Primary
Care.
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 2 9 9 – 3 0 7304Figure 2 shows the results of the bootstrap procedure based on
model A. From these graphs, we can deﬁne the range of certainty
of the group mean predicted error by group size: with a group size
of 10, errors range from þ0.3 to 0.2, and when the group size is
500, errors range from þ0.1 to 0. The group mean prediction
error decreased when the group mean predicted EQ-5D value
increased.We extended model A with the Charlson comorbidity index to
build model B, which improved the model and reduced the MAE
and RMSE slightly (Table 3). We recommend this model when the
Charlson comorbidity index is available. The performance of the
other estimated OLS models using the Dutch value set is shown
in Appendix 5 in Supplemental Materials found at http://dx.doi.
org/10.1016/j.jval.2014.11.006. We investigated the impact of
Fig. 2 – Group mean prediction errors, by group size (10, 25, 50, 100, 250, 500) and group mean predicted EQ-5D value. EQ-5D,
EuroQol ﬁve-dimensional questionnaire.
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independent observations by comparing a model that was based
on the entire data set with a model that was based on the
baseline measurement only. We found that the model based on
the entire data set had better predicted performance (i.e., lower
MAE and RMSE) than did the model based on the data set
including only the baseline measurements of RECODE. Merging
the three different data sets only slightly decreased the MAE from
0.153 (RECODE) to 0.152 (full data set). The RMSE was the lowest
(0.198) when the model was based on the GO-AHEAD trial.Sensitivity Analyses with US and UK EQ-5D Value Sets
When using US and UK value sets, the models based on the GO-
AHEAD data set had the lowest RMSE and the lowest MAE for
patients with an observed EQ-5D value below 0.5. Although the MAE
values of the models based on GO-AHEAD data set were somewhat
higher than those for the other models in case of milder impaired
health states, only the GO-AHEAD models predicted a mean EQ-5D
value that was not signiﬁcantly different from the observed mean
in the MARCH trial. Therefore, the recommended six-parameter
model for the US value set (model C) and the recommended six-
parameter model for the UK value set (model D) are based on the
GO-AHEAD data set. The predicted performances of these models
are given in Tables 3 and 4, and the algorithm can be found in
Table 2. The predictive ability of the model based on the US value
set (MAE 0.121; RMSE 0.155) was slightly better in comparison with
those of the model based on the UK value set (MAE 0.177; RMSE
0.229) and the models based on the Dutch value set (MAE 0.147 and
0.152; RMSE 0.196 and 0.198). The scatter plots of models C and Dlook quite similar to the scatter plot of model A. These plots reveal
that we were not able to produce accurate predictions on the
individual level. The mapping models underestimated the EQ-5D
scores for the mild health states, whereas they overestimated those
for the more severe health states. Appendix 6 in Supplemental
Materials found at http://dx.doi.org/10.1016/j.jval.2014.11.006
presents the results of the other estimated models for predicting
EQ-5D values based on US and UK value sets.Discussion
This study aimed to develop a model that predicts EQ-5D values
from CCQ scores, which can be used in the absence of directly
collected EQ-5D data. The recommended models were estimated
from the GO-AHEAD data set because it had the lowest MAE and
RMSE, especially for EQ-5D values below 0.5. The main reason is
that the GO-AHEAD data set had the widest variation in EQ-5D
values and the highest proportion of severe health states. On a
group level, the models predicted mean EQ-5D values that were
similar to the mean observed EQ-5D values in the same popula-
tion (internal validity) and the errors as percentage of the EQ-5D
range were lower than the typically found percentage of error of
the EQ-5D range up to 15% [22]. The predictive ability of the
models, however, varied with the severity of HRQOL impairment.
The mapping models underestimated the EQ-5D values for the
mild health states, whereas they overestimated those for the
more severe health states. This “misﬁt” is a general problem with
mapping studies because of regression to the mean [22,23]. The
overestimation and underestimation may cancel out when
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 2 9 9 – 3 0 7306predicting the overall mean EQ-5D value. The underestimation
for patients with good health states, however, is less than the
overestimation for patients with more severe health states [22].
This combination of ﬁndings may indicate reduced room for
improvement in severe health states. In typical Markov models of
COPD, patients with COPD are divided into different disease
severity states with different EQ-5D values. When using the
mapping models to predict EQ-5D values for these states, these
predictions are likely to be biased and the overestimation of the
low values and the underestimation of the high values would
probably no longer cancel each other out.
An important cause of the problematic map of the CCQ scores
onto EQ-5D values is the conceptual difference between the two
instruments. The correlation between the CCQ and the EQ-5D
was moderate (0.514), and PCA suggests that there are differ-
ences in the underlying constructs of the CCQ and the EQ-5D. The
EQ-5D dimension pain/discomfort formed a separate construct
on which none of the CCQ items loaded. Because this dimension
is an important driver of a reduced EQ-5D value in this popula-
tion, this is an important limitation. Furthermore, CCQ symptom
items 5 and 6 related to cough and phlegm production formed a
distinct construct, unrelated to any of the EQ-5D items.
If we compare our mapping model with the mapping model of
the SGRQ [7], another frequently used disease-speciﬁc HRQOL
instrument in COPD, the overall predictive ability is comparable.
The MAE and RMSE of the model that predicts EQ-5D values (US
value set) from SGRQ scores were 0.124 and 0.172, respectively [7],
and the MAE and RMSE of our model that predicts EQ-5D values
(US value set) from CCQ scores were 0.121 and 0.155, respectively.
Unfortunately, we cannot compare the misﬁt (i.e., underestima-
tion and overestimation of the EQ-5D values) of the model with
the SGRQ because a scatter plot of predicted and observed EQ-5D
values is not presented in the SGRQ mapping study.
This is the ﬁrst mapping study that developed models for EQ-
5D value sets of different countries. Because the model coefﬁ-
cients differ between countries, future mapping studies are
recommended to account for different value sets of the EQ-5D.
Apart from the fact that we investigated a wide range of different
models with increasing complexity for different EQ-5D value sets,
the strength of our study lies in the large number of observations
compared with previous mapping studies [6]. Using repeated EQ-
5Dmeasurements of the same patients as unique observations, as
previous mapping studies also did, increased the predictive ability
of the model. The bootstrap procedure showed to which extent
the accuracy of the mapping increases when they are estimated
in a larger sample size. These results are consistent with the
study from Grootendorst et al. [24]. The fact that the model
estimated from the GO-AHEAD trial performed best demon-
strates, however, that not only the size of the data set matters
but also the variation in EQ-5D values as we mentioned earlier. A
wide range of disease severity is a premise for undertaking
mapping [22].
A limitation of this study is that the numbers of patients with
an EQ-5D value of less than 0.5 was relatively small and 25% of
the observations were at full health. The ﬁnal models were based
on OLS regression because generalized linear models and Tobit
models did not improve the prediction. Some studies suggest that
the prediction performance of mapping models may be improved
by using more complex models such as the censored least
absolute deviation model [22]. Their use in previous mapping
studies, however, was limited (80% of the mapping studies used
OLS models [6]) and showed conﬂicting results on improvement
in predictive ability [22,25,26]. Recently, latent class analysis
showed some promising improvements in the predictive ability
of mapping models [27]. For future studies, it would be worth-
while to investigate whether these new modeling approaches will
actually lead to better predictability in patients with COPD.Conclusions
On a group level, the CCQ mapping models can predict mean EQ-
5D values that are similar to observed mean values if the patient
population is similar to the population in which the algorithm was
developed. The overestimating of the low observed EQ-5D values
and the underestimation of the high observed EQ-5D values,
however, limits its use in cost-effectiveness Markov models in
which utility estimates by disease severity state are required.
Therefore, mapping algorithms should be used cautiously.
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